Literature DB >> 10228078

Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants.

J M Groarke1, D C Pevear.   

Abstract

Pleconaril (VP 63843) is a novel orally bioavailable small molecule with broad antipicornavirus (enterovirus and rhinovirus) activity. Ten independently derived pleconaril-resistant variants of coxsackievirus B3 were isolated from cell culture. The molecular basis of drug resistance and the biologic properties of the drug-resistant viruses were investigated. RNA sequence analysis revealed amino acid changes in the drug-binding pocket of the resistant variants. Thermal stability studies showed the drug-resistant viruses to be significantly less stable than wild type virus. When evaluated in a murine model in which wild type virus infection is 100% lethal, the drug-resistant viruses showed attenuated virulence with both reduced mortality and delayed time to death. Virus titers in heart and spleen were dramatically lower in drug-resistant virus-infected mice than in wild type virus-infected animals. The study results indicate that pleconaril-resistant virus variants are attenuated and significantly less virulent than drug-sensitive wild type virus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10228078     DOI: 10.1086/314758

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

Review 1.  Nosocomial spread of viral disease.

Authors:  C Aitken; D J Jeffries
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

2.  Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.

Authors:  Hong-Mei Liu; Jason A Roberts; Deborah Moore; Barbara Anderson; Mark A Pallansch; Daniel C Pevear; Marc S Collett; M Steven Oberste
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

3.  Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.

Authors:  Daniel C Pevear; Frederick G Hayden; Tina M Demenczuk; Linda R Barone; Mark A McKinlay; Marc S Collett
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice.

Authors:  Ludek Eyer; Antoine Nougairède; Marie Uhlířová; Jean-Sélim Driouich; Darina Zouharová; James J Valdés; Jan Haviernik; Ernest A Gould; Erik De Clercq; Xavier de Lamballerie; Daniel Ruzek
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

5.  Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone.

Authors:  Shin-Ru Shih; Mun-Chung Tsai; Sung-Nien Tseng; Kuo-Fang Won; Kak-Shan Shia; Wen-Tai Li; Jyh-Haur Chern; Guang-Wu Chen; Chung-Chi Lee; Yen-Chun Lee; Kuan-Chang Peng; Yu-Sheng Chao
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.

Authors:  Liang Sun; Adam Meijer; Mathy Froeyen; Linlin Zhang; Hendrik Jan Thibaut; Jim Baggen; Shyla George; John Vernachio; Frank J M van Kuppeveld; Pieter Leyssen; Rolf Hilgenfeld; Johan Neyts; Leen Delang
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

7.  VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.

Authors:  Rebecca M Ledford; Nitesh R Patel; Tina M Demenczuk; Adiba Watanyar; Torsten Herbertz; Marc S Collett; Daniel C Pevear
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 8.  Presentation, diagnosis, and management of enterovirus infections in neonates.

Authors:  Mark J Abzug
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Immune responses and the emergence of drug-resistant virus strains in vivo.

Authors:  Dominik Wodarz; Alun L Lloyd
Journal:  Proc Biol Sci       Date:  2004-06-07       Impact factor: 5.349

10.  In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.

Authors:  S L Binford; P T Weady; F Maldonado; M A Brothers; D A Matthews; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.